KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Consolidated Net Income (2018 - 2025)

Castle Biosciences' Consolidated Net Income history spans 7 years, with the latest figure at -$2.3 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income fell 124.43% year-over-year to -$2.3 million; the TTM value through Dec 2025 reached -$24.2 million, down 232.41%, while the annual FY2025 figure was -$24.2 million, 232.41% down from the prior year.
  • Consolidated Net Income for Q4 2025 was -$2.3 million at Castle Biosciences, down from -$501000.0 in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $9.6 million in Q4 2024 and bottomed at -$29.2 million in Q1 2023.
  • The 5-year median for Consolidated Net Income is -$5.6 million (2021), against an average of -$8.4 million.
  • The largest annual shift saw Consolidated Net Income plummeted 1039.38% in 2023 before it skyrocketed 471.71% in 2024.
  • A 5-year view of Consolidated Net Income shows it stood at -$13.4 million in 2021, then tumbled by 54.08% to -$20.6 million in 2022, then soared by 87.49% to -$2.6 million in 2023, then surged by 471.71% to $9.6 million in 2024, then plummeted by 124.43% to -$2.3 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Consolidated Net Income are -$2.3 million (Q4 2025), -$501000.0 (Q3 2025), and $4.5 million (Q2 2025).